The San Antonio Breast Cancer Symposium (SABCS) held December 8-12, 2015 is designed to provide the latest experimental research on breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.
BCC partner Grazia de Michele is attending this year’s symposium with a scholarship from Advocates for Breast Cancer. A fitting group to attend SABCS, the organization’s mission is to unite breast cancer advocates to fund groundbreaking research, share education, improve patient care and find a cure, stages 0-4.
The Alamo Breast Cancer Foundation (ABCF) based in San Antonio, TX established a vital Patient Advocate Program as a component of the SABCS in 1996 and also offers scholarships each year to patient advocates who have completed NBCC’s Project LEAD Scientific Institute and have scientific knowledge of breast cancer through various programs. Alamo runs the ‘Hot Topics’ sessions each year where researchers meet with advocates, discuss the findings, and answer questions.
You’ll find an overview of some of the key studies to be presented at this year’s SABCS at Cancer Today, the quarterly magazine of the American Association for Cancer Research (AACR). Read More.
If you use twitter, there will be a Twitter chat on Friday, Dec. 11 at 2 p.m. ET, hosted by AACR and Cancer Today on research presented at SABCS as well as general topics of interest. Cancer Today (@CancerTodayMag) will moderate the chat. Follow along using the hashtag #sabcschat.
For all tweets related to the symposium follow the hashtag #SABCS15. Our own Grazia de Michele will also be live tweeting from the meeting. Follow her at @bc_consortium.
A Few Twitter Highlights
@CultPerfectMoms @ESchattner @jenniegrimes @Groz_P @corrie_painter @a4breastcancer @Majormac1 @AmazzoneFuriosa pic.twitter.com/goUmV8X7h3
— Kelly Shanahan (@stage4kelly) December 9, 2015
ER+ breast cancer recurring after 15 year #SABCS15 — BC Consortium (@BC_Consortium) December 9, 2015
We don’t know how many people have metastatic breast cancer #SABCS15 — BC Consortium (@BC_Consortium) December 8, 2015
#SABCS15 Germany started a national registry to include relapse, found distribution of subtypes similar to early stage — Corrie Painter, PhD (@corrie_painter) December 8, 2015
#SABCS15 “significant overall improvement of six more months” I hate hearing that this is as good as we’ve got. #stagefourdeservesmore — Jennie Grimes (@jenniegrimes) December 8, 2015
Need to distinguish between scientific term “statistically significant” and “clinically meaningful benefit” #sabcs15 https://t.co/cP5Qk0plrH — Julie Gralow (@jrgralow) December 9, 2015
We still employ a one dose fits all approach for the endocrine treatment of breast cancer #SABCS15 — BC Consortium (@BC_Consortium) December 9, 2015
Maura Dickler: endocrine therapy better than chemo for ER+ metastatic breast cancer #SABCS15 — BC Consortium (@BC_Consortium) December 8, 2015
Radiation reduces recurrence by half, but absolute benefit is very little for low-risk subgroups. Also reduces mortality about 1/6. #SABCS15 — Karuna Jaggar (@karunajaggar) December 9, 2015
From Harris #SABCS15 local recurrence mainly driven by biology (not margin, EIC) w triple neg highest — Dr. Nimmi Kapoor (@DrNimmiKapoor) December 9, 2015
#SABCS15 So little research on young, pre-menopausal women. Where is the research on survival/recurrence after 10 years of Tamoxifen? — Johanna Kenney, EdD (@JohannaKenney) December 9, 2015
#dontignorestageiv #dyingforacure #SABCS15 @METUPorg people at Susan G. Komen lecture #bcsm pic.twitter.com/VjEdSvRnDx — BC Consortium (@BC_Consortium) December 9, 2015
